王学影

[摘要] 目的 探討曲美他嗪联合琥珀酸美托洛尔治疗冠心病心力衰竭患者的临床效果。 方法 分析辽宁省盘锦市中心医院2013年1月～2016年4月收治的60例冠心病心力衰竭患者的临床资料，采用随机数字表法进行分组，对照组（地高辛治疗组）30例和观察组（曲美他嗪联合琥珀酸美托洛尔治疗组）30例。观察两组患者治疗前后生命体征及心功能变化情况、临床疗效。 结果 两组患者治疗前收缩压（SBP）、舒张压（DBP）、心率（HR）、左心室舒张末期内径（LVEDD）、左心室收缩末期内径（LVESD）、左室射血分数（LVEF）、B型尿钠肽（BNP）比较，差异无统计学意义（P > 0.05）。两组治疗后SBP、DBP、BNP均低于治疗前，HR慢于治疗前，LVEDD、LVESD小于治疗前，LVEF高于治疗前，差异有统计学意义（P < 0.05）。观察组治疗后SBP、DBP、BNP均低于对照组，HR慢于对照组，LVEDD、LVESD小于对照组，LVEF高于对照组，差异有统计学意义（P < 0.05）。观察组总有效率高于对照组，差异有统计学意义（P < 0.05）。 结论 曲美他嗪联合琥珀酸美托洛尔治疗冠心病心力衰竭患者的临床症状改善明显，效果良好，值得临床推广应用。

[关键词] 曲美他嗪；琥珀酸美托洛尔；冠心病；心力衰竭

[中图分类号] R541.4 [文献标识码] A [文章编号] 1673-7210（2017）01（b）-0131-04

Clinical effect of Trimetazidine combined with Metoprolol Succinate in the treatment of patients with coronary disease and heart failure

WANG Xueying

Department of Cardiology， Central Hospital of Panjin City， Liaoning Province， Panjin 124000， China

[Abstract] Objective To explore clinical effect of Trimetazidine combined with Metoprolol Succinate in the treatment of patients with coronary disease and heart failure. Methods Clinical data of 60 patients with coronary disease and heart failure in Central Hospital of Panjin City， Liaoning Province from January 2013 to April 2016 were analyzed. All patients were divided into two groups by random number table method， control group （digoxin therapy group） was 30 cases and observation group （Trimetazidine combined with Metoprolol Succinate therapy group） was 30 cases. The vital signs changing， heart function changing before and after treatment， clinical effect between two groups were observed. Results SBP， DBP， HR， LVEDD， LVESD， LVEF， BNP of two groups before treatment were compared， with no statistical difference （P > 0.05）. SBP， DBP， BNP of two groups after treatment were lower than before treatment， HR of two groups after treatment was slower than before treatment， LVEDD， LVESD of two groups after treatment were less than before treatment， LVEF of two groups after treatment was higher than before treatment， the differences were statistically significant （P < 0.05）. SBP， DBP， BNP of observation group after treatment were lower than those of control group， HR of observation group after treatment was slower than that of control group， LVEDD， LVESD of observation group after treatment were less than those of control group， LVEF observation group after treatment was higher than that of control group， the differences were statistically significant （P < 0.05）. Total effective rate of observation group was higher than that of control group， the difference was statistically significant （P < 0.05）. Conclusion Clinlcal symptom of Trimetazidine combined with Metoprolol Succinate in the treatment of patients with coronary disease and heart failure can improve obviously， the effect is good， it is worthy of clinical popularization and application.

[Key words] Trimetazidine； Metoprolol Succinate； Coronary disease； Heart failure

冠状动脉粥样硬化性心脏病又被称为冠心病，其主要是冠心病患者冠状动脉发生粥樣硬化，诱发血管管腔出现狭窄或者发生阻塞，进而造成心肌细胞缺血、缺氧，心肌坏死，心肌纤维化，心室出现重塑，心脏不同程度扩大，心律失常，从而发生心力衰竭，威胁患者的生命[1-2]。冠心病心力衰竭目前引起临床的广泛重视，治疗冠心病心力衰竭药物较多，其中包括美托洛尔、曲美他嗪，但是两者联合应用治疗效果的研究却鲜有报道[3-4]。本研究主要探讨曲美他嗪联合琥珀酸美托洛尔治疗冠心病心力衰竭患者的临床效果。

1 资料与方法

1.1 一般资料

选取辽宁省盘锦市中心医院（以下简称“我院”）2013年1月～2016年4月收治的60例冠心病心力衰竭患者的临床资料进行分析，依据随机数字表法进行分组，对照组30例，其中男18例，女12例；年……